巴西罕见病临床研究:挑战与机遇
Larissa Pozzebon da Silva1,2,3, Taiane Alves Vieira4,5, Gabriela Leiria da Silveira1,2
1Rare Diseases Brazil Research Group (DR Brasil), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Journal of community genetics
|May 14, 2025
概括
由于政策变化和合作努力,巴西罕见病的临床研究正在增长. 尽管存在监管障碍,但巴西在罕见病临床试验中为不同患者群体提供了独特的机会.
科学领域:
- 公共卫生 公共卫生
- 临床研究 临床研究
- 流行病学 流行病学
背景情况:
- 罕见疾病影响到7-1200万巴西人,构成了严重的公共卫生挑战.
- 巴西罕见病的流行病学数据不完整,需要共同努力.
- 巴西对罕见病患者综合护理政策 (2014) 旨在改善诊断和随访.
研究的目的:
- 为巴西罕见病的临床研究景观提供概述.
- 突出巴西开展罕见疾病临床试验的机遇和挑战.
- 讨论监管框架及其对罕见疾病研究的影响.
主要方法:
- 审查巴西临床研究政策和监管框架.
- 对巴西罕见病研究现状的分析.
- 讨论涉及研究伦理委员会 (CEP) 和国家研究伦理委员会 (CONEP) 的伦理审查过程.
主要成果:
- 巴西的监管机构,包括安维萨 (巴西卫生监管机构),监督临床研究批准.
- CEP和CONEP的伦理评估是严格的,尽管批准时间表可能很长.
- 最近的监管调整旨在简化临床试验批准过程.
结论:
- 在巴西进行临床研究提供了独特的机会,因为巴西的患者人数庞大而多样化.
- 合作举措和不断变化的监管环境对于推进罕见疾病临床试验至关重要.
- 改善临床试验参与有望为患有罕见疾病的人提供更好的患者结果和更好的生活质量.
相关概念视频
Case Studies
11.3K
There are many research methods available to psychologists in their efforts to understand, describe, and explain behavior and the cognitive and biological processes that underlie it.
11.3K
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Investigation of Disease Outbreaks
74
Multistate foodborne outbreaks pose significant public health risks and require meticulous investigation to identify sources and implement control measures. The Centers for Disease Control and Prevention (CDC) utilizes a dynamic seven-step process for these investigations, integrating data from laboratories, interviews, and environmental assessments to protect public health.Outbreak Detection: The detection of multistate outbreaks typically begins with PulseNet, the CDC's national laboratory...
74


